Technical Analysis for BCLI - Brainstorm Cell Therapeutics Inc.

Grade Last Price % Change Price Change
grade C 3.77 -3.08% -0.12
BCLI closed down 3.08 percent on Monday, May 20, 2019, on 76 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Down
See historical BCLI trend table...

Date Alert Name Type % Chg
Bollinger Band Squeeze Range Contraction 0.00%
BB Squeeze + Lower Band Touch Range Contraction 0.00%
Below Lower BB Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
20 DMA Resistance Bearish -3.08%
Bollinger Band Squeeze Range Contraction -3.08%
BB Squeeze Started Range Contraction -3.08%
Fell Below 20 DMA Bearish -1.57%
MACD Bearish Signal Line Cross Bearish -1.57%
Crossed Above 20 DMA Bullish -5.04%

Older signals for BCLI ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders, such as amyotrophic lateral sclerosis (ALS), Parkinson's disease, and multiple sclerosis. It holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. The company's NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor and brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. It is developing NurOwn, an autologous adult stem cell product for the treatment of ALS. Brainstorm Cell Therapeutics Inc. also has agreements with Hadasit Medical Research Services and Development Ltd. to conduct its ALS clinical trials at the Hadassah Medical Center. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics was founded in 2000 and is based in New York, New York.
Biotechnology Biology Stem Cells Multiple Sclerosis Parkinson's Disease Amyotrophic Lateral Sclerosis Neurochemistry Neurodegenerative Diseases Induced Stem Cells Adult Stem Cell Neurodegenerative Disorders Mesenchymal Stem Cell Stem Cell
Is BCLI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 5.35
52 Week Low 2.92
Average Volume 61,445
200-Day Moving Average 3.6982
50-Day Moving Average 4.022
20-Day Moving Average 3.9405
10-Day Moving Average 3.927
Average True Range 0.1228
ADX 17.96
+DI 14.8608
-DI 26.8787
Chandelier Exit (Long, 3 ATRs ) 3.7116
Chandelier Exit (Short, 3 ATRs ) 4.1084
Upper Bollinger Band 4.1023
Lower Bollinger Band 3.7787
Percent B (%b) -0.03
BandWidth 8.212156
MACD Line -0.0386
MACD Signal Line -0.0249
MACD Histogram -0.0136
Fundamentals Value
Market Cap 71.03 Million
Num Shares 18.8 Million
EPS -0.32
Price-to-Earnings (P/E) Ratio -11.78
Price-to-Sales 0.00
Price-to-Book 15.80
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.97
Resistance 3 (R3) 3.98 3.92 3.93
Resistance 2 (R2) 3.92 3.87 3.92 3.92
Resistance 1 (R1) 3.85 3.84 3.82 3.84 3.91
Pivot Point 3.79 3.79 3.78 3.79 3.79
Support 1 (S1) 3.72 3.74 3.69 3.71 3.63
Support 2 (S2) 3.66 3.71 3.66 3.62
Support 3 (S3) 3.59 3.66 3.61
Support 4 (S4) 3.58